Continuing its strong sales performance this year into the third quarter has led Germany’s PharmaSGP GmbH to raise its guidance for 2024.
Growth In Germany And Italy Prompts PharmaSGP To Raise Guidance
PharmaSGP has added an additional €5m to the top-end of its sales guidance after recording a double-digit gain Italy and outpacing the growth of the OTC market in Germany.
More from Earnings
More from Geography
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.